1. The Chinese Journal of Clinical Pharmacology was established in 1985 as a bi-monthly publication distributed domestically and internationally. It is supervised by the China Association for Science and Technology and sponsored by the Chinese Pharmacological Society. The editorial office is based at Peking University's Institute of Clinical Pharmacology, with co-sponsorship from Peking University Medical School, Peking University Medical Press Co., Ltd., and Southern Medical University Nanfang Hospital.
The journal is a top-tier academic publication in the field of pharmacology. It primarily focuses on reporting academic achievements related to clinical drug research and bridging the gap between basic and drug-related research in the field of clinical pharmacology in China. This includes pharmacology before drug marketing and Phase I-IV clinical trial research, post-marketing clinical pharmacology research, drug evaluation, personalized drug therapy, and the latest developments in pre- and post-marketing drug research and development domestically and internationally. It also publishes drug management policies and regulations related to new drug evaluation, guides the correct and standardized implementation of new drug clinical trials, improves the quality and management of clinical drug trials in China, aligns new drug clinical trial research with international standards, enhances the level of clinical pharmacology and drug therapy in China, ensures the effectiveness and safety of drug use for the people, and contributes to the development of clinical pharmacology in China.
The primary readers of the journal include researchers and managers in the field of clinical pharmacology, clinical physicians, pharmacists, pharmacology and toxicology researchers, faculty and students in medical schools, technical personnel engaged in drug research, development, production, and management, as well as pharmaceutical management and research personnel. The journal is classified as a core natural science journal (Category C) in China, listed in Peking University's ""Chinese Core Journal Overview,"" a source journal in the Chinese Science and Technology Paper Statistics Source Journal (Chinese Science and Technology Core Journal), a source journal in the National Torch Program project ""China Science Citation Database Source Journal,"" and a source journal in the China Academic Journal Comprehensive Evaluation Database. It is also included in the China National Knowledge Infrastructure (CNKI) and Wanfang Data Resource System (Chinalnfo) digital journal group. The journal is indexed in Chemical Abstracts (USA), Western Pacific Region Index Medicus (WPRIM), Ulrich's Periodicals Directory (online version) (USA), Cambridge Scientific Abstracts (USA), Japan Science and Technology Agency Database, and cited in Medline and SCEE (USA), supported by the China Association for Science and Technology's Fine Science and Technology Journal Project.
2. The journal's sections include Clinical and Basic Bridging Research, Research Methods, Bacterial Resistance Monitoring, Innovative Drug Tolerance Research, Pharmacokinetics and Bioequivalence Research, Bridging Pharmacodynamics Research, Adverse Drug Reactions, Drug Reviews, Rational Drug Use, Reader's Corner, New Drug Introductions, Reviews, Drug Evaluation and Management, Expert Consensus, and Reviews.
3. For article submissions, authors are required to provide an institutional introduction letter, author authorization letter, declare no multiple submissions, no authorship disputes, and undergo a confidentiality review. For thesis submissions, a recommendation letter from the supervisor is required. Funded projects should be approved by the state, have titles consistent with the content, and include approval documents.
4. Submission Writing Requirements
4.1 Article Requirements: The article should have a clear argument, reliable data, logical structure, clear hierarchy, and concise language. The full text of research papers (including Chinese and English abstracts, keywords, main text, references, and tables) should not exceed 8000 words, while reviews and critiques should not exceed 8000 words.
4.2 Title: The title should accurately reflect the specific content of the article, with a word limit generally within 20 words, not exceeding 30 words. Avoid subtitles, series articles, and minimize the use of codes (abbreviations or custom terms; provide the full term upon first use).
4.3 Authors: Authors should be individuals capable of addressing the issues raised in the article, and their number should be limited. Academic advisors may be listed as authors based on the actual situation, but it is recommended to acknowledge them in the ""Acknowledgments"" section. In case of changes in authorship, a letter of certification from the institution is required. Please provide the contact author and their contact information (indicate mobile phone as MP, Tel, and E-mail) at the bottom of the first page. The author's Chinese Pinyin should have the surname capitalized followed by the given name with the first letter capitalized, separated by a hyphen. For example: Han Qide, HAN Oi-de.
4.4 Keywords: Ideally 5-8 keywords selected from the title, abstract, and main text, preferably from medical subject headings. Chinese and English keywords should be consistent.
4.5 Main Text: Avoid excessive hierarchical headings, limited to 3 for research articles and adjusted as needed for reviews. Use a hierarchical numbering format like 1.1.1.1.1.1 (specific cases may vary) with spaces after the sequence number, without bullet points. Funded projects should be listed at the bottom of the first page with the project name and number. Changes in author addresses and visiting scholars should be indicated at the bottom of the first page. Acknowledgments (for assistance, data provision, and materials) should be placed at the end of the main text.
4.6 Introduction: The introduction should have a solid foundation, including the current domestic and international research status, research background, and clear research objectives. The word count should be within 300 words.
4.7 Drugs, Reagents, Animals, Objects, and Instruments: Specify specifications, standards, and sources. Use the ""Chinese Pharmacopoeia"" (Chemical Industry Press, 1997) and ""International Nonproprietary Names, INN"" (WHO, 2014) for drug names. New drugs approved by the National Health Commission of the People's Republic of China should be referred to by their approved names. The English name should be provided when a drug name is first mentioned. Clearly state the species for animals, using the full English name. Published methods can generally be cited for established techniques. For new or substantially improved methods, detail the enhancements. For newly developed methods, provide a comprehensive description for reproducibility.
4.8 Medical Terminology: Use standardized (correct) medical terms, such as ""polymyxin B"" (polymyxin), ""rapamycin"" (sirolimus), ""diazepam"" (diazepam), ""indomethacin"" (indomethacin), ""pethidine"" (pethidine), ""total glycosides of Rehmannia"" (total glycosides of Rehmannia), ""macrolides"" (macrolides), ""alcohol"" (ethanol), ""calcium channel blockers"" (calcium channel blockers), ""myocardial infarction"" (myocardial infarction), ""reflux"" (reflux), ""hemodynamics"" (hemodynamics), ""anorexia"" (anorexia).
4.9 Italics: Microbial genus and species (Escherichia coli), quantity symbols (mass m, time), statistical symbols (sample size, sample mean, test probability P), Latin phrases (in vitro, in vivo); foreign names of author affiliations and journal/book titles in references (abbreviated); pharmacokinetic symbols, except English abbreviations (e.g., RSDAUC, CL), should be in italics.
4.10 Units of Measurement and Symbols: Follow national and international standards. Time units should be written as ""(seconds), min (minutes) (hours), d (days)""; 1M (molar concentration) should be written as 1mol·L^-1, and 1 mpm should be written as 1 r·min. Injection routes: intravenous (iv), intramuscular (im), intraperitoneal (ip), subcutaneous (sc), intracerebroventricular (icv), intra-arterial (ia), oral (po) in italics; drugs or reagents should have the name written first followed by quantity and unit (e.g., methanol 1 m, not 1 m methanol).
4.11 Numbers: Years should be written in full, e.g., 1998, not '98; quantifiers and ordinals should be in Arabic numerals, e.g., 20th century, 90s, 2nd time. Numerical values should generally be between 0.1 and 1000. Use ""1x10"" for 10^1. 100 x 100 mm should be written as 100 mm x 100 mm, and 80 + 3 mm should be written as 80 mm + 3 mm or (80+3) mm. Percentages like 5~48% should be formatted as 5%~48%, and percentage tolerance like 56±4% should be formatted as (56±4)%.
4.12 Significant Figures: Reflect the reliability of measurement values; measurements should not exceed the precision of the measuring instrument. Retain two significant figures after the decimal point.
4.13 Tables and Figures: Avoid using figures or tables where text can convey the information clearly. Text, tables, and figures should not duplicate information. Use English for tables and figures, with bilingual titles (Chinese, English) and self-explanatory headings. Coordinate names in figures should preferably be represented by quantity symbols, not names, and values should be rounded (e.g., 40.23 should be changed to 40). Use three-line tables, align numbers vertically in cells, and leave one space on each side. Use , ... for table notes, place P-values at the bottom of the table (use <, > to indicate, not raw data like P=0.003), and specify the comparison. Use symbols like ○, ●, △, ▲, ◇, ◆ for figures.
4.14 Spacing: Use half-width spaces between primary and secondary units (e.g., Peking University Medical School); use 1/4 space between numerical units, symbols, and variables (e.g., 20 g:whonet 5.0:1 mmHg = 0.133 kPa).
4.15 Discussion: Provide a brief analysis and reasoning of experimental results without repeating them. Discuss results and viewpoints from relevant domestic and international reports, expressing the author's perspective. Propose further research ideas. Conclusions and closing remarks in the main text should be clear and conclusive, avoiding the term ""summary.""
4.16 References: Cite original sources authors have consulted, avoid secondary references, internal data, translations, abstracts; accepted but unpublished articles can be cited with ""In press"" after the journal name. Authors are responsible for the accuracy and completeness of cited references. Follow the provided format.
Journal: Author (up to 3 authors listed in full, for more than 3 authors list 3 authors followed by ""et al.""). Title [J]. Journal Name, Year, Volume(Issue): Start Page-End Page.
[1] Sun Lulu, Shan Ailian, Lv Yuan, et al. Pharmacokinetic Study of Cefoperazone/Tazobactam (3:1) for Injection in Healthy Chinese Subjects [J]. Chinese Journal of Clinical Pharmacology. 2012. 28(8): 584-587.
[2] NG S Y, LIN L, SOH B S, et al. Long noncoding RNAs in development and disease of the central nervous system [J]. Trends in Genetics. 2013. 29(8): 461-468.
Book: Author, Book Title, Volume. Edition, Place of Publication: Publisher, Year: Start Page-End Page, or Author (Editor or Chapter Author). Title // Editor. Book Title. Volume. Edition. Place of Publication: Publisher, Year: Start Page-End Page.
[3] Li Jiatai. Clinical Pharmacology [M]. 2nd ed. Beijing: People's Health Publishing House. 1998. 3-17.
[4] MCPHERSON R A, PINCUS M R. Henry's Clinical Diagnosis and Management by Laboratory Methods [M]. 22nd ed. Philadelphia: Elsevier Inc. 2011: 485.
Patent: Patent Applicant, Patent Title: Patent Country, Patent Number, Publication Date or Announcement Date.
[5] HANNE B, DAVID R. Conjugate for targeted delivery of bone growth factors: Europe, 512844. 1992-11-11.
Collection of Papers: Author. (Year). Title of the Collection. Place of Publication: Publisher, Starting Page-Ending Page. or
Author (Ed. or Chapter Author). (Year). Title of the Chapter. In Editor's Name (Ed.), Title of the Collection. Place of Publication: Publisher, Starting Page-Ending Page.
[6] Lv Y. How to Utilize Data on Bacterial Drug Resistance Monitoring // Beijing University Institute of Clinical Pharmacology, Beijing Physician Association Infection Specialist Branch, Chinese Pharmacological Society Clinical Pharmacology Professional Committee, Chinese Journal of Clinical Pharmacology. Proceedings of the 11th National Conference on Clinical Pharmacology of Anti-Infective Drugs. Beijing: Beijing University Institute of Clinical Pharmacology, 2014: 3-9.
Thesis/Dissertation: Author, Title. Institutional Address: Institution Name, Year.
[7] Li CY. Study on the Inhibitory Effect and Mechanism of Pomegranate Peel Extract on Stress-induced Gastrointestinal Dysmotility in Rats [D]. Jinan, Shandong: Shandong Normal University, 2010.
Standardized Book: Standard Number, Standard Name. Year: Start Page-End Page.
[8] Ch.P(2010)Vol Ⅱ, Chinese Pharmacopoeia 2010 Edition [S] Part 2, 2010: 52-54.
Electronic Publication: Author, Title of the Electronic Document. Journal Name, Year, Volume: Start Page-End Page or
Institution Name and Address. Announcement Date and Download Date, Access Path.
[9] Chen Z, Xu H. Anti-inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis [J/OL]. Evidence-based Complementary and Alternative Medicine, 2014, 20: e78-e80. 2014-12-02 (Publication Date) [2015-05-06] (Download Date). http://www.ncbi.nlm.nih.gov/pubmed/25525444.
[10] National Medical Products Administration, General Administration Announcement on the Release of Three Technical Guidance Principles for the Selection and Determination of Reference Preparations for Oral Solid Dosage Forms (No. 61 of 2016)[EB/0L].2016-05-21[2021-08-27]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhefg/20160318210001633.html.
[11]FDA. Food and Drug Administration Code ofFederal Regulations Tiule21 ,Part 312 investiga-tional new drug application[EB/0L].2002-03-04 [2021 -06-03]. hitps://ecfr. feder-alregister.gov/eurrenl/title-2l/chapter-l/subchapter-D/part-312/subpart -B/section-312.23.
Upon receiving your submission to our journal's email (as we have only one dedicated email address and no official website), the editorial department will assign a reference number and provide a receipt. Please keep this number for future inquiries regarding your submission. The journal reserves the right to make edits to submissions. Authors will receive a proofreading copy via email for review. Unless in exceptional cases, please refrain from making significant changes to the proofreading copy and return it promptly. Authors will be promptly notified if their submission is not selected for publication. The journal holds the copyright for published articles, and reproduction or republication without permission is prohibited. Authors will receive remuneration and two complimentary copies of the journal upon publication.
Address: Institute of Clinical Pharmacology, Peking University, 38 Xueyuan Road, Haidian District, Beijing, China. Editorial Department of The Chinese Journal Of Clinical Pharmacology.
Please submit your contributions to our sole submission email: cicp1985@163.com. For inquiries regarding submissions or other related matters, you can also contact us at 010-82802540.